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Abstract
Introduction: Patients with lipodystrophy experience selective or generalized atrophy of adipose
tissue. The disruption of lipid metabolism results in an increased risk for development of metabolic
syndrome and coronary artery disease. Currently, the mutations responsible for approximately half
of lipodystrophy patients are known, but new techniques and examination of different types of
genetic variation may identify new disease-causing mechanisms.
Case presentation: A 53-year-old woman of African descent was referred to a tertiary care
endocrinology clinic for treatment of severe insulin resistance, treatment-resistant hypertension and
dyslipidemia. After all known lipodystrophy-causing mutations were excluded by DNA sequencing,
the patient was found to have triple X syndrome after an initial investigation into copy number
variation using a high-density oligonucleotide microarray. The patient also had a previously
unobserved duplication of 415 kilobases of chromosome 5q33.2. This is the first case report of a
patient with lipodystrophy who also had triple X syndrome.
Conclusion: While we cannot make a direct link between the presence of triple X syndrome and
partial lipodystrophy, if unrelated, this is an extremely rare convergence of syndromes. This patient
poses an interesting possibility regarding the influence triple X syndrome may have on an individual
with other underlying lipodystrophy susceptibility. Finally, impending large-scale case-control and
cohort copy number variation investigations will, as a by-product, further document the prevalence
of triple X syndrome in various patient groups.
Introduction
Lipodystrophies are a family of disorders characterized by
selective or generalized atrophy of adipose tissue [1]. The
molecular mechanisms of many forms of lipodystrophy
have been discovered by carefully selecting patients to
ensure phenotypic homogeneity and performing molecu-
lar genetic analysis to identify mutations. Sequencing of
both functional candidate genes, from knowledge of lipid
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tional candidate genes, identified through linkage analy-
sis, have uncovered mutations in genes responsible for
two subtypes of congenital generalized lipodystrophy
(AGPAT2, BSCL2), three subtypes of familial partial
lipodystrophy (LMNA, PPARG, CAV1), and some patients
with acquired partial lipodystrophy (LMNB2) [2]. The
metabolic syndrome, a constellation of symptoms includ-
ing dyslipidemia, specifically increased plasma triglycer-
ides and decreased high-density lipoprotein cholesterol
(HDL), dysglycemia, insulin resistance, increased visceral
obesity and increased cardiovascular risk, is common in
patients with lipodystrophy [2]. Lipodystrophy mutations
may have a direct impact on pathways of insulin resistance
and lipid metabolism; thus, the identification of addi-
tional molecular mechanisms could improve insight into
the more common form of metabolic syndrome. Cur-
rently, ~50% of patients with clinically diagnosed lipody-
strophy have no known molecular basis (RAH,
unpublished observations). The development of new
strategies and the examination of new types of variation
are required to further elucidate lipodystrophy
pathogenesis.
Copy number variations (CNVs) were first identified as a
relatively high frequency source of genetic variation in
2004 [3]. CNVs are submicroscopic deletions or duplica-
tions of genomic DNA above the resolution of sequencing
techniques (>~1 kb). Since 2006, large efforts have been
made to categorize and map the spectrum of CNVs in the
unaffected population [4]. Here we report a patient with
partial lipodystrophy who had no mutations in any
known lipodystrophy gene and who we subsequently
found to have triple X syndrome during genome-wide
screening to detect lipodystrophy-associated CNVs using
oligonucleotide microarrays.
Case presentation
A 53-year-old woman from Ghana was referred for severe
insulin resistance, treatment-resistant hypertension and
dyslipidemia. She was first diagnosed with type 2 diabetes
at age 40 and was treated with oral hypoglycemic agents
until age 51 when insulin was added. She presented to the
emergency room with exertional chest heaviness, dyspnea,
and epigastric discomfort, however no definite cardiac
event was diagnosed. She had a history of burning pain
and numbness in her feet, diffuse muscle pains consistent
with a chronic pain syndrome, and bilateral frozen
shoulders. The patient has a strong family history for
early coronary heart disease: her father had a myocardial
infarction (MI) in his early 60s, her mother had three MIs,
one sister had coronary artery bypass surgery in her 40s
and another sister had an MI in her 30s. The patient’s only
family history of diabetes was in her maternal grand-
father’s brother.
Current medications included 120 units of insulin daily,
amlodipine, valsartan, hydrochlorothiazide, rosuvastatin,
ezetimibe, metformin, enteric coated acetylsalicylic acid
(ASA), rabeprazole, amitriptyline, meloxicam, K-lyte, and
magnesium.
On physical examination, she hada typical Dunnigan-type
lipodystrophic habitus, including lipoatrophy of the lower
extremities but sparing of fat deposits in the abdominal
region, face and neck. Although the age of onset of her
lipodystrophy is not known, she has had the same
physiognomy for most of her adult life. Her radial pulse
was 70 beats/minute and blood pressure was 150/
85 mmHg. Her weight was 61.8 kg, height 162 cm, and
body mass index 23.5 kg/m
2. On cardiovascular exami-
nation, soft bruits were heard over both carotids, a 2/6
systolic ejection murmur was heard over the pericardial
region and transient pitting edema of the lower extremities
was detected bilaterally. On neurological examination, she
had absent ankle jerk reflexes and decreased sensation in
the area of the upper shin. She had marked acanthosis
nigricans on the back of her neck. No other pertinent
findings were observed on physical examination; specifi-
cally no ocular, dermatological, or abdominal findings.
Her laboratory results included (reference range) fasting
glucose of 8.8 mmol/L (4.0-6.0 mmol/L), glycated
hemoglobin 16.9% (4.1-6.5%), total cholesterol
7.2 mmol/L (4.3-6.5 mmol/L), triglycerides 3.35 mmol/L
(0.67-3.15 mmol/L), low-density lipoprotein cholesterol
(LDL) 4.8 mmol/L (2.3-4.3 mmol/L), HDL 0.9 mmol/L
(1.0-2.4 mmol/L). Cardiac investigations, including elec-
trocardiogram, echocardiogram, exercise and pharmaco-
logical stress echocardiogram, gated single photon
emission computed tomography (SPECT) perfusion
study, cardiac catheterization and coronary angiography,
were all negative specifically showing no significant
ischemia or coronary artery disease.
The patient was found to carry no mutation in any of the
known lipodystrophy-causing genes (LMNA, PPARG,
BSCL, AGPAT2, LMNB2, CAV1) by exon-by-exon sequence
analysis. Genomic DNA was extracted from peripheral
blood leukocytes and 250 ng was used in each genotyping
assay. The high-density oligonucleotide microarrays
(chips) used for analysis were the Affymetrix GeneChip
Human Mapping 500 K array set (Santa Clara, CA, USA).
The chips were processed using established protocols in
the London Regional Genomics Centre. Copy number
determination was performed using 130 normal controls
and 40 lipodystrophy cases (Figure 1) with Partek
Genomics Suite version 6.3 (St Louis, MO, USA). No log
transformations or data normalizations were used, but
probes were corrected for fragment length, sequence, and
guanine-cytosine (GC) content. Two CNVs were identified
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X chromosome, and a duplication of 89 single nucleotide
polymorphism (SNP) probes over 415 kb of chromosome
5q33.2, from 154,979 kb to 155,394 kb (physical
position, NCBI reference build 36.2). No genes were
found in or within 300 kb of the 5q33.2 duplication.
Neither the duplication of 5q33.2, nor triple X syndrome,
was identified in any of the other lipodystrophy patients
or normal controls.
Discussion
We report the case of a patient with partial lipodystrophy,
who had no known molecular diagnosis, and who was
discovered to be a carrier of three X chromosomes after
genome-wide screening for CNVs (Figure 1). To our
knowledge, this is the first report of a patient with both
triple X syndrome and partial lipodystrophy. An addi-
tional 40 lipodystrophy patients with no known mutation
were investigated using a high-density oligonucleotide
microarray: among the 29 female lipodystrophy patients,
no other cases of triple X syndrome were observed. A
comprehensive amniocentesis screen of 34,910 children
for sex chromosome abnormalities reported the preva-
lence of triple X syndrome as 1 in 947 girls [5]. Thus, the
observation of a lipodystrophy patient with triple X
syndrome in a cohort of 29 women was surprising. Partial
lipodystrophy is rare, but estimates of prevalence are
difficult due to the heterogeneity of clinical diagnosis [6].
While collection of lipodystrophy patients is difficult due
to the low disease prevalence, karyotyping of additional
lipodystrophy patients would give better insight into the
frequency of triple X syndrome in this patient cohort. We
cannot make a direct link between triple X syndrome and
the lipodystrophy found in this patient, however it does
pose an interesting possibility regarding the influence
triple X syndrome may have on an individual with other
underlying susceptibility. If the triple X syndrome and
lipodystrophy found in this patient are incidental and
unrelated, this convergence of syndromes would be
extremely rare.
The CNV screen identified a large 415 kb duplication of
chromosome 5q33.2. To our knowledge, this duplication
has not been previously identified in a lipodystrophy
patient, in our normal controls, or in the public database
of genomic variants [3]. A large degree of CNV in this size
range has been identified in the ‘healthy’ population [3].
There are no known genes in or within 300 kb of the
duplication and no previously identified lipodystrophy
loci are found on chromosome 5q. Therefore, we conclude
that there is insufficient evidence at this point to support
further investigations specifically into a potential function
for the 5q33.2 duplication.
The most commonly reported findings in triple X
syndrome are tall stature, mild mental retardation,
behavioral problems, and premature ovarian failure [7].
None of the common findings in triple X syndrome were
present in our patient. Because karyotype analysis is not
part of the routine work-up for a patient with partial
lipodystrophy, our study is an example of how a large
cytogenetic abnormality that would otherwise remain
undiagnosed can be serendipitously identified after CNV
screening using high-density oligonucleotide arrays.
Attempts to map structural changes in healthy control
populations have revealed a large degree of variation [4].
As studies screen large case-control and cohort datasets for
CNV changes we will, as a by-product, further refine the
frequency and impact of large structural variations.
Within the literature, triple X syndrome cases have been
reported with gastrointestinal, renal, and urogenital
abnormalities [8], as well as gonadal dysgenesis, con-
genital adrenal hyperplasia, and central precocious pub-
erty [9]. Two triple X syndrome patients have been
reported with insulin resistance. One teenaged patient
mosaic for triple X syndrome had insulin resistance, tall
stature and disturbed behavior [10]. A second patient had
transient neonatal diabetes mellitus and later type 2
diabetes diagnosed at age 31, but was found to have a
concomitant uniparental paternal isodisomy of chromo-
some 6, subsequently linked to type 2 diabetes [11].
One limitation of the use of oligonucleotide arrays to
determine copy number is that it is not possible to
determine whether all cells contain the same genomic
structure. Patients with triple X syndrome have been
Figure 1. X chromosome probe intensity for copy number
determination. Copy number determination was performed
using 130 normal controls (65 men, 65 women) and 40
lipodystrophy cases (29 women, 11 men). Red dots represent
single nucleotide polymorphism intensity for 29 female
lipodystrophy patients. Green dots represent SNP intensity
for 11 male lipodystrophy patients. Blue dots represent single
nucleotide polymorphism intensity for the female
lipodystrophy patient diagnosed with triple X syndrome. For
the patient with triple X syndrome, probe intensities were
within the normal range for all other chromosomes, with the
exception of the duplication on 5q33.2 (data not shown).
Page 3 of 5
(page number not for citation purposes)
Journal of Medical Case Reports 2009, 3:8867 http://jmedicalcasereports.com/jmedicalcasereports/article/view/8867reported to be mosaic for chromosome number, such as
46, XX/47, XXX [10]. Moreover, without parental genotype
information, we are unable to determine the parental
source of the additional X chromosome.
In women, X-linked gene dosage equivalency is created by
the X-inactivation (also known as lyonization) of either
the maternally- or paternally-inherited X chromosome, as
well as any extra X chromosomes, in the late blastocyst
stage [12]. The inactive state is retained in all cells through
epigenetic inheritance [12]. Thus, men and women have
one transcriptionally active copy of the X chromosome.
Pseudo-autosomal regions of X, found near the telomere
of the short arm, are excluded from X-inactivation and are
also found on the Y chromosome, so all humans with two
sex chromosomes have two transcriptionally active copies
of these regions [12]. Genes that escape X-inactivation are
excellent candidates for involvement in the triple X
phenotype. The SHOX gene lies within the pseudo-
autosomal region and overdosage, as a result of triple X
syndrome, when combined with estrogen deficiency, has
been suggested to be responsible for the often tall stature
in women with three X chromosomes [10].
Insulin resistance and other metabolic disturbances are
more commonly identified in men with an extra X
chromosome [13]. The mechanism of insulin resistance
in patients with Klinefelter syndrome is unknown, but has
been suggested to be primarily mediated by a decrease in
insulin sensitivity due to increased truncal obesity and
decreased muscle mass secondary to hypogonadism [13].
However, testosterone treatment only partly corrected the
metabolic problems of a sample of patients [13]. Perhaps
an unknown factor on the additional X chromosome is
involved in the unfavorable fat distribution and insulin
resistance.
Conclusion
We report a patient with partial lipodystrophy including
severe insulin resistance in the absence of any known
lipodystrophy causing mutations discovered to have
triplication of the X chromosome during genome-wide
screening for CNV using a high-density oligonucleotide
microarray. This is the first report of a patient with both
lipodystrophy and triple X syndrome. As studies searching
for genetic determinants of various disorders screen large
patient populations for CNVs, we will gain greater insight
into not only the effect of small structural variations, but
as a by-product, the frequency and impact of triple X
syndrome.
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